Skip to main content
Clinical Trials/ACTRN12607000521426
ACTRN12607000521426Completed未知

The prevalence of Helicobacter pylori (Hp) infection in patients consecutively admitted during a 12-month period to the emergency unit of the A. Cardarelli Hospital of Naples for peptic ulcer disease complicated by haemorrhage after assumption of nonsteroidal anti-inflammatory drugs (NSAIDs): EMOFANS Study

Dr. Antonio Balzano0 sites80 target enrollmentStarted: October 10, 2007Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to -2147483648 No limit (—)
Sex
All

Inclusion Criteria

  • Patients with peptic ulcer disease complicated by haemorrhage (Hematemesis, melena, ematochezia, or with other clinical signs of blood loss - i.e., hemodynamic instability with hypotension and tachycardia) within 72 hours before admission;
  • Continuative or occasional use of nonsteroidal anti-inflammatory drugs within 30 days before admission;
  • Ulcer with a diameter of at least 5 mm;
  • Ability to understand and follow the protocol requirements;
  • Having given written informed consent form for study participation

Exclusion Criteria

  • Patients in treatment with antibiotics and proton-pump inhibitors within 4 weeks before the enrolment;
  • Patients with upper gastrointestinal neoplastic ulcer

Investigators

Sponsor
Dr. Antonio Balzano

Similar Trials

The prevalence of Helicobacter pylori... | Clinical Trial